

Investor Information

Successful participation of Exentis at institutional investor conference

- ◆ Exentis presents at the Commerzbank Swiss Equities Conference 2025
- ◆ Largest international investor conference in Switzerland
- ◆ Strong interest in license-based business model

Stetten, Switzerland, June 17, 2025 – Exentis Group AG, provider of the world's only technology platform enabling industrial additive large-scale manufacturing, participated for the first time in the Swiss Equities Conference in Interlaken last week at the invitation of Commerzbank.



Exentis presents to numerous interested institutional investors

The Swiss Equities Conference is the largest institutional investor conference in Switzerland for publicly listed Swiss companies. The multi-day event, organized by Commerzbank in cooperation with ODDO BHF, attracted more than 120 institutional investors from Switzerland and abroad, as well as approximately 70 listed Swiss companies. Exentis was one of the few companies not yet listed that was granted the opportunity to present its technology platform and license-based business model to a broad international investor audience.

Raju Willener, Chief Financial Officer of Exentis Group AG: "The invitation to participate in this renowned investor conference once again confirms the strong interest of leading European banks in our Swiss high-tech company as an attractive investment opportunity for institutional investors. Investors particularly emphasized the wide range of application possibilities of our technology in transformative future key industries as well as our stable and profitable business model focused on generating recurring revenues."

About Exentis

As a solution provider, Exentis has the only proprietary technology platform worldwide that allows for industrial additive large-scale production. Industrialized Additive Manufacturing is universally applicable. For industrial or clean room applications. With free choice of materials, such as metals, ceramics, polymers, pharmaceutical or bio-printing products. The highly flexible production technology combines rework-free component geometries with advantageous cost-benefit ratios. The cold printing process in use is sustainable and conserves materials as well as resources. Our customers can choose between exclusive in-house manufacturing under license agreements or having Exentis produce millions of applications for them as a contract manufacturer.

For further information please contact:

Benjamin del Fabro
Head of Investor Relations

+41 44 520 46 00
b.delfabro@exentis-group.com

Visit us also on our website at www.exentis-group.com.